Conference Coverage

Neither perioperative aspirin nor clonidine prevents MI

View on the News

Complex mechanisms underlie perioperative MI

Myriad, and sometimes opposing, mechanisms contribute to perioperative MI, including excess bleeding, dramatic fluid shifts, unrelenting tachycardia, myocardial stress with fixed coronary obstruction, profound hypo- or hypertension, coronary plaque rupture, and coronary spasm, said Dr. Prashant Vaishnava and Dr. Kim A. Eagle.

So it shouldn’t be surprising that a medical therapy aimed at one of these mechanisms may actually augment a different mechanism, and end up raising MI risk. "Aspirin may reduce coronary thrombosis at the expense of excess bleeding; clonidine may reduce hypertensive swings only to be countered by clinically important hypotension," they noted.

On balance, the POISE-2 results provide cogent evidence against the use of either perioperative aspirin or clonidine.

Dr. Vaishnava and Dr. Eagle are at the Samuel and Jean A. Frankel Cardiovascular Center at the University of Michigan Health System, Ann Arbor. They reported no potential conflicts of interest. These remarks were taken from their editorial accompanying the POISE-2 trial reports (New Engl. J. Med. 2014 March 31 [doi:10.1056/NEJMe1402976]).


 

FROM ACC 14

Similarly, it is not known why clonidine failed to be protective, but the investigators offered two possible reasons. First, the drug induced hypotension, which raises the risk of perioperative MI. And second, it also induced bradycardia, which may be a proxy for an overall adverse effect on heart rate control; this also can increase the risk of perioperative MI, they said.

The POISE-2 trial was supported by the Canadian Institutes of Health Research, the National Health and Medical Research Council of Australia, and the Spanish Ministry of Health and Social Policy. Bayer Pharma provided the aspirin used in the study, and Boehringer Ingelheim provided the clonidine and some funding. Dr. Devereaux reported ties to Abbott, Bayer Pharma, Boehringer Ingelheim, Covidien, Roche, and Stryker and; some of his associates reported ties to several industry sources.

Pages

Recommended Reading

First guidelines on pulmonary hypertension in sickle cell disease released
MDedge Cardiology
New heart valve guideline has more accessible format
MDedge Cardiology
Frailty assessment central to TAVR decision
MDedge Cardiology
Controversies in dual antiplatelet therapy post PCI
MDedge Cardiology
Corporate health care is here
MDedge Cardiology
TAVR: More procedural success with balloon-expandable valves
MDedge Cardiology
VIDEO: CoreValve self-expanding aortic valve beat surgical replacement
MDedge Cardiology
VIDEO: What explains SYMPLICITY HTN-3’s failure?
MDedge Cardiology
Survival after TAVR superior to surgery in high-risk aortic stenosis patients
MDedge Cardiology
Ineffective renal denervation blamed for trial’s failure
MDedge Cardiology